Abstract:Abstract High-grade serous ovarian cancer (HGSC) is the most common form of epithelial ovarian cancer, typically diagnosed at advanced stage with five-year survival of only 38%. Herein, we used 149 treatment-naïve and 65 after-treatment samples subjected to whole-genome sequencing from 55 HGSC patients to reconstruct evolutionary histories, characterize clonal compositions and intra- and inter-tumor heterogeneity, in order to identify mechanisms that drive treatment failure. Using clonal information from the phylogenetic trees we quantified intra- and intertumor heterogeneity and identified three types of clonal compositions corresponding to three evolutionary states (“adaptive”, “maintaining” and “evolving”) of treatment-naïve HGSC tumors. The branch depths from phylogenetic trees were used to quantify “clonal age” for each state. The “adaptive” state showed the highest clonal age, followed by the “maintaining” state, and the “evolving” being the youngest, least evolved tumor state. The three states have significantly different survival association, “evolving” the longest and “maintaining” the shortest (p = 0.029). Pathway analysis of genes harboring branch mutations revealed that the three states are characterized by unique signaling cascades, with MAPK, PI3K/AKT, and NOTCH signaling significantly enriched at “evolving”, “maintaining”, and “adaptive” states, respectively. Furthermore, we suggest two evolutionary trajectories originating from “evolving” state towards “maintaining” via PI3K/AKT activation and extensive cytokine signaling or towards “adaptive” state via RAS/RAF/MAP cascade. Overall, altered PI3K/AKT signaling was found in half of the patients, followed by alterations in NOTCH signaling enriched in 20% of patients. To explore the effect of treatment on evolutionary states we investigated clonal compositions and enriched pathways in the after-treatment samples. Interestingly, 62% of the neoadjuvant chemotherapy treated (three cycles of platinum & paclitaxel) samples remained in the same evolutionary state as compared to the treatment-naïve samples from the same patients, indicating that the neoadjuvant therapy does not significantly alter tumor composition. Analysis of relapse samples revealed that signal transduction via PI3K/AKT and NOTCH was enriched after the full course of treatment (including platinum-taxane chemotherapy, surgery, possible maintenance therapy with PARP inhibitors or angiogenesis inhibitors), which testifies for their central role in treatment failure. Taken together, our results show that integrating clonal composition and heterogeneity at diagnosis allows allocation of HGSC tumors into three states with different prognosis. Aberrations in PI3K/AKT or NOTCH signaling, distinctive for higher evolved “maintaining” and “adaptive” states, are key pathways to the development of chemoresistant clones. As the herein identified pathways can be targeted by several clinically approved drugs, our results provide a means to identify effective, combinatorial personalized treatments for HGSC patients at the relapse setting. Citation Format: Alexandra Lahtinen, Kari Lavikka, Yilin Li, Sanaz Jamalzadeh, Anni Virtanen, Rainer Lehtonen, Olli Carpén, Sakari Hietanen, Kaisa Huhtinen, Antti Häkkinen, Johanna Hynninen, Jaana Oikkonen, Sampsa Hautaniemi. Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr PR003.

Abstract IA006: Leveraging the extreme selection induced by therapeutic bottlenecks to subvert resistance via identifying evolutionarily-informed targets for orthogonal immunotherapy

Abstract 548: Exploiting pronounced selection pressure from therapeutic bottlenecks to identify orthogonal immunotherapy targets

Abstract A025: Adaptive therapy: Leveraging evolutionary dynamics for colorectal cancer management in vivo

Abstract PR006: Evolution of evolvability

Abstract A016: Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and promotes tumor heterogeneity

Abstract B008: Therapy-protective peristromal niches mediate positive ecological interaction between therapy-sensitive and therapy-resistant cells, altering the evolutionary dynamics of acquired targeted therapy resistance in lung cancers

Abstract A021: Evolutionary immunotherapy in NSCLC: An integrated approach

Abstract 3385: Modeling evolutionary fitness in resistant cancers based on a common adaptability trait

Abstract IA010: Unraveling mutation and selection to better understand early cancer evolution

Abstract A027: Detecting and modeling frequency-dependent evolution in serially passaged primary triple negative breast cancer patient derived xenografts

Functional genomic landscape of T-cell mediated cytotoxicity.

Abstract IA020: Dynamics of response and resistance to cancer therapy

Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer

Abstract 5100: Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade

Abstract 6943: Evolutionary dynamics under chemotherapy in small cell lung cancer: Insights from patient-derived xenotransplant models

Abstract 1989: Intratumor heterogeneity in EGFR-mutant lung tumors mediates targeted therapy resistance and formation of drug tolerant microenvironment

Abstract A013: Cell-extrinsic mechanisms of accelerated therapy resistance mediated by altered pharmacokinetics

Abstract PR003: Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer

Abstract 3287: Learning to target CDK4/6 inhibitor resistance via a breast cancer-specific atlas of cellular mechanisms

Abstract 2197: Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance

Abstract 5825: Non-genetic determinants driving the evolutional trajectories of drug-tolerant-persisters in KRAS Non-small cell lung cancer